申请人:Next Generation Labs, LLC
公开号:US10610526B2
公开(公告)日:2020-04-07
A composition suitable for use in nicotine replacement therapy products includes a nicotine product that includes a synthetic nicotine that is substantially free of one or more contaminants and/or impurities normally associated with tobacco-derived nicotine. For example, the synthetic nicotine is substantially free of one or more of nicotine-1′-N-oxide, nicotyrine, nornicotyrine, 2′,3-bipyridyl, cotinine, anabasine, and/or anatabine. The composition further comprises one or more pharmaceutically acceptable excipients, additives and/or carriers. The nicotine replacement therapy products may include any number of such products, including transdermal nicotine delivery patches, nicotine gums, synthetic chewing tobacco, synthetic snuff, and synthetic strips (e.g., dissolvable synthetic tobacco). Additionally, a method of treating nicotine addiction includes administering a nicotine replacement composition, e.g., via a nicotine replacement therapy product, to a user.
适用于尼古丁替代疗法产品的组合物包括尼古丁产品,该产品包括合成尼古丁,该合成尼古丁基本上不含通常与烟草衍生尼古丁相关的一种或多种污染物和/或杂质。例如,合成尼古丁基本上不含尼古丁-1′-N-氧化物、烟碱、去甲烟碱、2′,3-联吡啶、可替宁、安那巴新和/或安那他滨中的一种或多种。组合物还包括一种或多种药学上可接受的赋形剂、添加剂和/或载体。尼古丁替代疗法产品可包括任何数量的此类产品,包括透皮尼古丁递送贴片、尼古丁口香糖、合成咀嚼烟草、合成鼻烟和合成烟草条(如可溶解的合成烟草)。此外,一种治疗尼古丁成瘾的方法包括向使用者施用尼古丁替代组合物,例如通过尼古丁替代疗法产品。